EUVIMEDEUVIMED entdecken
MetaanalyseÜbersichtsarbeitOpen Access · CC BY 4.0

Meta Analysis of DHA and EPA Supplementation on Cardiovascular Outcomes and Atrial Fibrillation Risk

Sepideh Karkon Shayan iD, Rosull Saadoon Abbood, Sarah F Al-Taie, Paria Ganji Nataj, Maksudova Malika Khamdamjonovna iD, Siamak Aminnezhad, Yasaman Ghodsi Boushehri iD, Jabbarov Jamoliddin Sindorovich iD, Ali Sinehsepehr, Farshad Zare, Seyed Abbas Pakmehr, Elham Abdollahi und 1 weitere

Pharmacology Research & Perspectives · 2026-06 · 14 (3)

DOI: 10.1002/prp2.70265 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Pharmacology Research & Perspectives, online erschienen am 17.05.2026. Verfasst von Sepideh Karkon Shayan und 12 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Gonabad University of Medical Sciences, Gonabad, Iran. Hauptthemen laut MEDLINE: Atrial Fibrillation, Docosahexaenoic Acids, Eicosapentaenoic Acid, Dietary Supplements. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cardiovascular diseases (CVD) remain to impose a main global burden of morbidity and mortality despite advances in anticipation and treatment. Omega‐3 fatty acids, mainly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have been extensively studied for potential cardioprotective effects, yet their impact on cardiovascular outcomes remains debated due to heterogeneity in formulation, dose, and patient subgroups. This meta‐analysis evaluated the effects of EPA and DHA supplementation on major adverse cardiovascular events (MACE) and atrial fibrillation (AF), including postoperative AF (POAF), in patients with established CVD. A systematic search of Embase, PubMed/MEDLINE, Scopus, and Web of Science (January 2010–December 2021) identified randomized controlled trials (RCTs) of combined EPA + DHA supplementation in secondary prevention or perioperative settings. Data were synthesized using RevMan v5.3 with a random‐effects model, and study quality was assessed via the Cochrane RoB 2 tool. From 3682 records, 25 RCTs ( n = 25 578 patients) were included. Pooled analysis showed no significant reduction in MACE (effect estimate 0.042 ± 0.0499, Z = 0.850, 95% CI [−0.055, 0.140], p = 0.396; low heterogeneity) or AF/POAF incidence (trend toward reduction: −0.198 ± 0.1498, Z = −1.319, 95% CI [−0.491, 0.096], p = 0.187; modest heterogeneity). Neutral findings likely reflect moderate‐dose combined EPA + DHA use, limited subgroup reporting on metabolic comorbidities (e.g., diabetes, hypertriglyceridemia) or concomitant therapies (e.g., statins), and high background guideline‐directed medical therapy reducing residual risk. Although omega‐3 fatty acids exert anti‐inflammatory, antithrombotic, and lipid‐modulating effects, this analysis indicates no broad benefit in reducing MACE or AF risk with combined moderate‐dose EPA + DHA in heterogeneous post‐event populations. Recent evidence highlights more MACE reductions with high‐dose purified EPA monotherapy in high‐metabolic‐risk subgroups, balanced against dose‐dependent AF increases at high doses (> 1.5 g/day). Future large‐scale RCTs should prioritize biomarker‐verified compliance, metabolic/concomitant therapy stratification, and formulation‐specific comparisons to define targeted therapeutic roles. Trial Registration: This study has been registered in PROSPERO, and the registration code is 642795

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationDocosahexaenoic AcidsEicosapentaenoic AcidDietary SupplementsCardiovascular DiseasesHumansRandomized Controlled Trials as TopicSecondary Prevention

Stichwörter der Autor:innen

atrial fibrillationcardiovascular diseasedocosahexaenoic acideicosapentaenoic acidmajor adverse cardiovascular event

Substanzen

Docosahexaenoic AcidsEicosapentaenoic Acid

Autor:innen und Institutionen

  • School of Medicine, Gonabad University of Medical Sciences, Gonabad, Iran.
  • Medical Laboratory Techniques Department, College of Health and Medical Technology, University of Al-Maarif, Anbar, Iraq.
  • Department of Biotechnology, College of Science, University of Baghdad, Baghdad, Iraq.
  • School of Public Health, Dalian Medical University, Dalian, China.
  • Department of Faculty and Hospital Therapy No. 2, Nephrology and Hemodialysis, Tashkent State Medical University, Tashkent, Uzbekistan.
  • Cardiovascular Research Center, Tehran University of Medical Sciences, Tehran, Iran.

ORCID-Profile: Sepideh Karkon Shayan, Maksudova Malika Khamdamjonovna, Yasaman Ghodsi Boushehri, Jabbarov Jamoliddin Sindorovich, Milad Vahedinezhad

Zitieren

APA

Shayan, S. K., Abbood, R. S., Al-Taie, S. F., Nataj, P. G., Khamdamjonovna, M. M., Aminnezhad, S., Boushehri, Y. G., Sindorovich, J. J., Sinehsepehr, A., Zare, F., Pakmehr, S. A., Abdollahi, E., & Vahedinezhad, M. (2026). Meta Analysis of DHA and EPA Supplementation on Cardiovascular Outcomes and Atrial Fibrillation Risk. Pharmacology Research & Perspectives, 14(3). https://doi.org/10.1002/prp2.70265

Vancouver

Shayan SK, Abbood RS, Al-Taie SF, Nataj PG, Khamdamjonovna MM, Aminnezhad S, et al. Meta Analysis of DHA and EPA Supplementation on Cardiovascular Outcomes and Atrial Fibrillation Risk. Pharmacology Research & Perspectives. 2026;14(3). doi:10.1002/prp2.70265

BibTeX
@article{Shayan2026,
  author = {Shayan, Sepideh Karkon and Abbood, Rosull Saadoon and Al-Taie, Sarah F and Nataj, Paria Ganji and Khamdamjonovna, Maksudova Malika and Aminnezhad, Siamak and Boushehri, Yasaman Ghodsi and Sindorovich, Jabbarov Jamoliddin and Sinehsepehr, Ali and Zare, Farshad and Pakmehr, Seyed Abbas and Abdollahi, Elham and Vahedinezhad, Milad},
  title = {Meta Analysis of DHA and EPA Supplementation on Cardiovascular Outcomes and Atrial Fibrillation Risk},
  journal = {Pharmacology Research & Perspectives},
  year = {2026},
  volume = {14},
  number = {3},
  doi = {10.1002/prp2.70265}
}
Kostenlos starten →